Measuring CD8 Immune States in Four Tissue Specimens
Matched RNA, protein, and spatial measurements revealed differences in cytotoxic-signature expression within the CD8 compartment.
Immune-state differences across samples
We compared four selected wells from a 14-well Singular G4X analysis. The fraction of CD8 cells expressing a cytotoxic RNA signature ranged from 24.6% to 63.8%. Reporting the fraction within the CD8 compartment distinguishes this measure from total immune-cell abundance.
| Sample | Tissue metadata | CD8 cells | Signature-positive cells | Fraction of CD8 cells |
|---|---|---|---|---|
| H01 | Lung | 825 | 526 | 63.8% |
| G04 | Other | 219 | 103 | 47.0% |
| E01 | Lung | 72 | 19 | 26.4% |
| C01 | Lung | 338 | 83 | 24.6% |
These differences define a measurable immune-state feature for follow-up alongside spatial organization and cell abundance. Testing an association with treatment response requires documented outcomes and a separate patient-level evaluation.
Measurement and study scope
The G4X measurements combined a 341-gene RNA panel with 16 protein markers measured in the same cells. Cell typing used the standard 425-class MiraTyper model with tissue constraints and protein-informed decoding. A CD8 cell was flagged as cytotoxic-signature positive when at least one transcript was detected from GZMB, GZMA, GZMK, GZMH, PRF1, GNLY, or NKG7.
This is a descriptive comparison of four selected wells, with three recorded as lung and one as “Other.” The signature measures transcriptional state; it does not directly measure cell killing. These results do not establish treatment-response prediction, and the four wells do not constitute an independent validation cohort.
Source: MiraOmics Elephas / Singular G4X follow-up analysis, July 16, 2026. Counts and fractions are taken from the current per-well results table; percentages are rounded to one decimal place.
Related publication: von Euw et al., Cancer Research 86(7 Supplement), abstract 1389 (AACR 2026). This publication reports a separate cytokine-profiling study; the four-sample CD8 results above come from the MiraOmics follow-up analysis.